This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ganjoo, K. N. Articles by Einhorn, L. H. Search for Related Content PubMed PubMed Citation Articles by Ganjoo, K. N. Articles by Einhorn, L. H. Social Bookmarking                            What's this?

Positron Emission Tomography Scans in the Evaluation of Postchemotherapy Residual Masses in Patients With Seminoma

From the Department of Medicine, Division of Hematology/Oncology, Indiana University Medical Center, Indianapolis, IN.

Address reprint requests to Lawrence H. Einhorn, MD, Indiana University, Indiana Cancer Pavilion, 535 Barnhill Dr, Route 473, Indianapolis, IN 46202.

PURPOSE: To assess the ability of positron emission tomography (PET) scans in differentiating between necrosis and viable seminoma in postchemotherapy (PC) residual disease.

PATIENTS AND METHODS: We conducted a prospective study of 29 patients with seminoma at Indiana University. All patients had PC residual disease. Computed tomography and PET scans were performed for 19 patients after primary chemotherapy (group A) and for 10 patients after salvage chemotherapy (group B).

RESULTS: In group A, the PC masses were 3 cm in 14 patients, less than 3 cm in three patients, and not quantified in two patients. All of the patients in group A had negative PET scan results and have had stable or decreasing residual mass size (median follow-up duration, 11.5 months; range, 6 to 26 months). In group B, the PC masses were 3 cm in four patients, less than 3 cm in five patients, and not quantified in one patient. One patient had a positive PET scan result for a posterior mediastinal mass. Pathologic diagnosis of the PET-positive mass showed only necrotic tissue. The same patient had a negative PET scan of the retroperitoneal mass but relapsed in that area. Overall, of patients in group B, five have stable or decreasing mass (median follow-up duration, 8 months; range, 7 to 22 months), and five had relapsed disease.

CONCLUSION: PET scans have no apparent benefit in PC evaluation of residual masses in bulky seminoma.

Presented in part at the Thirty-Fifth Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, May 15-18, 1999.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Iwasa, M. Ando, M. Ono, T. Hirata, M. Yunokawa, E. Nakano, K. Yonemori, T. Kouno, C. Shimizu, K. Tamura, et al. Relapse with Malignant Transformation After Chemotherapy for Primary Mediastinal Seminoma: Case Report Jpn. J. Clin. Oncol., July 1, 2009; 39(7): 456 - 459. [Abstract] [Full Text] [PDF]

				M. De Santis, A. Becherer, C. Bokemeyer, F. Stoiber, K. Oechsle, F. Sellner, A. Lang, K. Kletter, B. M. Dohmen, C. Dittrich, et al. 2-18fluoro-deoxy-D-glucose Positron Emission Tomography Is a Reliable Predictor for Viable Tumor in Postchemotherapy Seminoma: An Update of the Prospective Multicentric SEMPET Trial J. Clin. Oncol., March 15, 2004; 22(6): 1034 - 1039. [Abstract] [Full Text] [PDF]

				M. De Santis, C. Bokemeyer, A. Becherer, F. Stoiber, K. Oechsle, K. Kletter, B. M. Dohmen, C. Dittrich, and J. Pont Predictive Impact of 2-18Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography for Residual Postchemotherapy Masses in Patients With Bulky Seminoma J. Clin. Oncol., September 1, 2001; 19(17): 3740 - 3744. [Abstract] [Full Text] [PDF]

				S F Barrington Whole body applications of positron emission tomography in oncology Imaging, September 1, 2001; 13(3): 185 - 196. [Abstract] [Full Text] [PDF]